HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run ...
The firm will pay $45 million upfront for several new targeted agents that it plans to pair with isotopes to develop both ...
This marks the first US approval for AstraZeneca and Daiichi Sankyo's Trop-2-directed antibody drug conjugate.
Despite Leqembi's initial slow sales, the firm's CEO cited areas for the drug's growth and ambitions for an antisense ...
Although Pfizer is not among the drugmakers suing the government to block negotiations, it has said the program will hinder drug R&D and innovation.
The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and ...
The FDA also approved Qiagen's Therascreen KRAS RGQ PCR kit as a companion diagnostic to identify KRAS G12C-mutant patients.
With new treatments in neurology, and more in development in cardiology and autoimmune diseases, precision medicine is moving ...
In OurHealth Study, Researchers Seek Genetic Underpinnings of Cardiovascular Disease in South Asians
Researchers from the Broad Institute, Mass General, Stanford, and elsewhere are investigating why patients with South Asian ...
The firm, which plans to use the ticker symbol "MAZE" on the Nasdaq, develops drugs designed to mimic the protective effects ...
On the third day, drugmakers provided updates on precision medicines for cancer and Alzheimer's, and Grail talked about the launch of a new version of the Galleri test.
The firm aims to advance two breast cancer therapies in HR-positive, HER2-negative advanced breast cancer this year.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback